Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
Mark Wilson - Navigating Innovation in a Slow-Moving Pharma Industry

Mark Wilson - Navigating Innovation in a Slow-Moving Pharma Industry

Georgia Lewis: 11 March 2026

Mark Wilson - Presentation at UK Pharmaceutical & MedTech Innovations event.ISPE UK Affiliate - 12/2/2026 Listening to Mark’s reflections on his 20...

Read More
Optimising Cryovial Filling and Cryopreservation for Reliable Cell Functionality

Optimising Cryovial Filling and Cryopreservation for Reliable Cell Functionality

3P innovation: 10 March 2026

An Integrated Equipment Workflow for Consistent Post-Thaw Viability and Function Recovery

Read More
The challenges of developing combination products: Regulatory complexity and the case for a holistic development strategy

The challenges of developing combination products: Regulatory complexity and the case for a holistic development strategy

Dr. Dave Seaward: 15 February 2026

Drug–device combination products are becoming a defining feature of modern pharmaceutical portfolios, shaping how therapies differentiate, extend...

Read More